APVO
Aptevo Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.84
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.84
From 52W high−94.84%
Volume40794.00
Market cap$3.33M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.84
From 52W high
−94.84%
Volume
40794.00
Market cap
$3.33M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
32.1
MomentumView details →
1D Return
+0.00%
YTD Return
−80.38%
SummaryUpdated Jun 1, 2026
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company emerged as a spinoff focused on developing innovative immunotherapeutic treatments for various forms of cancer. Aptevo specializes in creating bispecific antibodies, which are engineered proteins designed to simultaneously target two different antigens to enhance the body's immune response against cancer cells. The company has developed proprietary platform technologies called ADAPTIR and ADAPTIR-FLEX to create these specialized therapeutic candidates.
Similar companies
Latest newsMore news →
Aptevo Therapeutics announced clinical trial results for its lead candidate mipletamig, reporting a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations.17d agoAptevo Therapeutics entered into a 50/50 collaboration with Niowave to develop radiopharmaceutical therapeutics.37d agoAptevo Therapeutics reported financial results for the quarter ended June 30, 2026, and provided a business update on its clinical programs and collaborations.37d ago